Gene · 10892
Papers2,863
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,863
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignancies. | Blood Cancer Discov | 2026 | 42814116 | PubTator, text mining | PubMed |
| Running on Empty Signals: What Human MALT1 Deficiency Reveals About Immune Control. | J Immunol Res | 2026 | 42745540 | PubTator, text mining | PubMed |
| Targeting intracellular immune regulatory molecules for cancer immunotherapy in solid tumors. | Crit Rev Oncol Hematol | 2026 | 42732787 | PubTator, text mining | PubMed |
| Effect of MALT1 inhibition by MI‑2 on the microglial phenotype switch, inflammatory cytokine secretion, neuronal loss and oxidative stress in Alzheimer's disease. | Int J Mol Med | 2026 | 42695408 | PubTator, text mining | PubMed |
| Novel agents and evolving strategies in Waldenström macroglobulinemia: clinical trial updates from ASH 2025. | Exp Hematol Oncol | 2026 | 42665819 | PubTator, text mining | PubMed |
| Epitranscriptomics, immunometabolism, and NETosis: unlocking novel mechanisms of traditional Chinese medicine in COPD. | Front Immunol | 2026 | 42614789 | PubTator, text mining | PubMed |
| A role for the protease MALT1 in EBV-mediated B-cell transformation by Latent Membrane Proteins 1 and 2. | Leukemia | 2026 | 42595846 | PubTator, text mining | PubMed |
| From Dynamics to Diagnosis and Therapy: A Multiscale Computational Framework for MALT1-Targeted Cancer Theranostics. | J Chem Inf Model | 2026 | 42573397 | PubTator, text mining | PubMed |
| [Clinicopathological features and prognosis of marginal zone lymphoma with aberrant CD10 expression]. | Zhonghua Bing Li Xue Za Zhi | 2026 | 42547419 | PubTator, text mining | PubMed |
| The requirement of MALT1 activity for the growth of adult T cell leukemia/lymphoma. | iScience | 2026 | 42542590 | PubTator, text mining | PubMed |
| Case Report: pulmonary MALT lymphoma with BIRC3::MALT1 fusion and indeterminate PET/CT findings. | Front Oncol | 2026 | 42539472 | PubTator, text mining | PubMed |
| MOF promotes venous thromboembolism in lung cancer by activating the YBX1-MALT1-NF-κB-PAI-1 axis, possibly through histone crotonylation. | J Biol Chem | 2026 | 42480704 | PubTator, text mining | PubMed |
| A novel linker region truncating variant in BCL10 underlies a leaky immunodeficiency phenotype. | Pediatr Allergy Immunol | 2026 | 42473108 | PubTator, text mining | PubMed |
| lncRNA MIR4435-2HG modulates the malignant progression of glioblastoma through the miR-181d-5p/MALT1/NF-κB signaling pathway. | J Mol Histol | 2026 | 42443662 | PubTator, text mining | PubMed |
| Efficacy of personalized traditional Chinese medicine massage combined with tuina in the treatment of pediatric congenital heart disease and malnutrition intolerance. | Pak J Med Sci | 2026 | 42257080 | PubTator, text mining | PubMed |
| Loop dynamics govern MALT1 activation revealed by integrative AlphaFold, MD, and NMR analysis. | Sci Rep | 2026 | 42162184 | PubTator, text mining | PubMed |
| A novel case of autosomal recessive CARD11 loss-of-function underlying impaired antiviral immunity and a review of literature. | Clin Transl Immunology | 2026 | 42110384 | PubTator, text mining | PubMed |
| Novel Compounds as MALT1 Inhibitors for Treating Cancer. | ACS Med Chem Lett | 2026 | 41982709 | PubTator, text mining | PubMed |
| Integrated spatial transcriptomics and pan-cancer XGBoost modeling uncover spatial drivers of immune exclusion and predict immunotherapy response. | Cancer Immunol Immunother | 2026 | 41925746 | PubTator, text mining | PubMed |
| Toward ultimate NMR resolution with deep learning. | Sci Adv | 2026 | 41894514 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10892/papers